Key facts
- Anaconda Biomed’s last known valuation is $108.1M (Dec 2019).
- It has raised $50.6M; the latest was Later Stage VC in Jan 2025.
- Notable investors include INNVIERTE SICC, Omega Funds, Asabys Partners, EIT Health, Frédéric Picq — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Anaconda Biomed
- ·The full record, as it builds
Funding rounds
No funding rounds for Anaconda Biomed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Anaconda Biomed
Developer of intravascular catheter-based medical devices designed to enable mechanical thrombectomy for stroke treatment. The company's platform provides funnel catheters with flow restriction, suction force optimization, and clot retrieval support, enabling healthcare professionals to safely remove clots, reduce embolization risk, improve navigation in neurovascular procedures, and enhance treatment outcomes in acute ischemic stroke cases.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2015
- Employees
- 45
- Website
- anaconda.bio/
- Ownership
- Privately Held (backing)
Anaconda Biomed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anaconda Biomed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anaconda Biomed in its N-PORT filings yet. We sweep new filings monthly.